Skip to contentP
Pure Bioscience, Inc.
P
PUREPure Bioscience, Inc. Q2 2014 · 10-Q
Revenue$41.00K$41.00K−84.4% vs Q2 2013 Net Income-$2.48M-$2.48MN/M vs Q2 2013 EPS Diluted-$0.10-$0.10N/M vs Q2 2013 Operating Income-$3,221,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pure Bioscience, Inc. · CIK 1006028 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$1,777,000N/M Margins · derivedOperating margin-7856.1%−7167.9 pt vs Q2 2013
Net margin-6053.7%−5360.1 pt vs Q2 2013
ended Jan 31, 2014 · filed Mar 13, 2014 · 41 d after period end